Systemic administration of dynorphin A(1–13) markedly inhibits different behavioural responses induced by cocaine in the mouse
-
Add time:09/02/2019 Source:sciencedirect.com
The effects of systemic administration (i.p.) of dynorphin A(1–13) on the cocaine-induced behavioural alterations in the mouse were determined by using multi-dimensional behavioural analyses, based upon a capacitance system. A 1.0 mg/kg dose of cocaine did not influence behaviour, while increasing doses to 3–30 mg/kg produced a significant increment in the frequency of behaviour, such as linear locomotion, circling, rearing and grooming. Although a 1.0 mg/kg dose of dynorphin A(1–13) alone produced a significant decrease in grooming behaviour, larger doses (3.0 and 10.0 mg/kg) of the peptide failed to affect different behaviour. The cocaine (3.0 mg/kg)-induced increases in linear locomotion, circling and rearing behaviour were significantly inhibited by dynorphin A(1–13) (10.0 mg/kg). The inhibitory effects of dynorphin A(1–13) (10.0 mg/kg) were antagonized by the opioid antagonist Mr 2266 (5.6 mg/kg). It is thus possible that the systemic administration of dynorphin A(1–13) inhibits different behavioural responses induced by cocaine through the blood-brain barrier, although the instability of amino acid bonds or the relatively large molecular weight of dynorphin A(1–13), may result in the failure to demonstrate opioid activity by the peptide after systemic administration.
We also recommend Trading Suppliers and Manufacturers of dynorphin A (1-13), Ala(2)-Trp(4)- (cas 104746-05-6). Pls Click Website Link as below: cas 104746-05-6 suppliers
Prev:[D-Ala2,(F5)Phe4]-dynorphin1–13-NH2 (DAFPHEDYN): A potent analog of dynorphin 1–13
Next:Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research reportEffect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat09/09/2019
- ArticleDynorphin a-(1–13)-morphine interactions: Quantitative and qualitative eeg properties differ in morphine-naive vs. Morphine-tolerant rats09/08/2019
- Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide09/07/2019
- ArticleEffects of high intravenous doses of dynorphin A(1–13) on tail flick latency and central nervous system histology in rats09/06/2019
- Dynorphin A (1–13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias09/05/2019
- Dynorphin-A-(1–13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord09/04/2019
- Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats09/03/2019
- [D-Ala2,(F5)Phe4]-dynorphin1–13-NH2 (DAFPHEDYN): A potent analog of dynorphin 1–1309/01/2019
- Suppression by dynorphin A-(1–13) of the expression of opiate withdrawal and tolerance in mice☆08/31/2019


